Key Takeaways
Is Depression a Chemical Imbalance? The Short Answer
The claim that depression is a chemical imbalance, usually meaning too little serotonin, is not supported by current evidence. A 2022 umbrella review in Molecular Psychiatry concluded that the main areas of serotonin research provide “no consistent evidence of there being an association between serotonin and depression”[1].
That does not make brain chemistry irrelevant to depression. The National Institute of Mental Health (NIMH) describes the disorder as involving genetic, biological, environmental and psychological factors[6], and researchers still disagree about how much the serotonin system matters for particular patients.
What has not held up is the simple version: one chemical running low, causing one illness, which a pill tops back up. How many people have depression, by age, sex and state, is tracked on the depression statistics page.
Chemical imbalance theory of depression
The idea that depression results from abnormal levels or activity of brain chemicals, particularly serotonin, and that antidepressants work by correcting it[1][7]. In research papers it appears as the monoamine hypothesis, or the serotonin hypothesis when it refers to serotonin alone.
Related Terms
Source: Moncrieff et al., Molecular Psychiatry (2022)
Where the Chemical Imbalance Theory Came From
The theory started as a research hypothesis. In 1965 psychiatrist Joseph Schildkraut proposed that depression was associated with low levels of norepinephrine, and later researchers turned the focus to serotonin[7].
It reached the public largely through advertising for selective serotonin reuptake inhibitors (SSRIs). A 2005 essay in PLOS Medicine found that U.S. direct-to-consumer SSRI campaigns “largely revolved around the claim that SSRIs correct a chemical imbalance caused by a lack of serotonin”[7].
One television advertisement for sertraline (Zoloft) said depression may be due to a chemical imbalance and that “Zoloft works to correct this imbalance”[7]. The drug’s FDA-approved label was more guarded, stating only that its mechanism of action “is presumed to be linked” to blocking serotonin reuptake[8].
Psychiatry itself also carried the idea. A 2022 analysis of highly cited academic literature from 1990 to 2010 found that most reviews of the causes of depression supported the serotonin hypothesis, and all six textbooks examined gave it some degree of endorsement[9].
The diagnostic system never adopted it. The DSM, the American Psychiatric Association’s manual of diagnoses, does not list serotonin as a cause of any mental disorder[7]. Diagnosis rests on symptoms lasting at least 2 weeks, with a physical exam, interview and lab tests used to rule out look-alikes such as thyroid disorders[6]; the full criteria are in DSM-5 depression criteria.
What the 2022 Serotonin Umbrella Review Found
The 2022 umbrella review was led by Joanna Moncrieff of University College London[1]. It assessed 17 studies, including 12 systematic reviews and meta-analyses, across six lines of serotonin research, with literature searches running to December 2020[1].
None of the six produced consistent support. Serotonin’s main breakdown product, 5-HIAA, showed no association with depression, and a meta-analysis of plasma serotonin covering 1,869 people found no relationship[1].
Genetics gave the clearest answer. The two largest and highest-quality studies of the serotonin transporter (SERT) gene, with 115,257 and 43,165 participants, found no association with depression and no interaction between the gene, stress and depression[1]. Broader heritability findings are covered in is depression genetic.
Tryptophan depletion studies lower the amino acid the body uses to make serotonin. They found no effect on mood in most healthy volunteers (566 people) and weak evidence of an effect in 75 people with a family history of depression[1].
Imaging studies of serotonin receptors and the serotonin transporter showed weak and inconsistent differences, and the authors noted that effects of prior antidepressant use were not reliably excluded[1]. They added that some evidence was consistent with the possibility that long-term antidepressant use itself reduces serotonin concentration[1].
What Each Line of Serotonin Research Showed
| Research area | Largest sample | Finding |
|---|---|---|
| 5-HIAA (serotonin metabolite) in body fluids | 1,002 | No association with depression |
| Plasma serotonin, cohort studies | 1,869 | No relationship; lower levels linked to antidepressant use |
| 5-HT1A receptor binding | 561 | Weak, inconsistent evidence |
| Serotonin transporter (SERT) binding | 1,845 | Weak, inconsistent; prior drug use not excluded |
| Tryptophan depletion, healthy volunteers | 566 | No effect in most |
| Tryptophan depletion, family history of depression | 75 | Weak evidence of an effect |
| SERT gene association and gene-stress interaction | 115,257 and 43,165 | No association, no interaction |
Largest single analysis in each research area assessed by Moncrieff et al., literature searched to December 2020[1].
1Studies within an area overlap and were not pooled, so sample sizes cannot be added together.
Sources
- •Moncrieff et al., Molecular Psychiatry, 2022
Why Some Researchers Say the Review Went Too Far
The review drew a formal rebuttal. In 2023, 35 researchers led by Sameer Jauhar of King’s College London argued in the same journal that its conclusion was overstated, citing methodological weaknesses, selective reporting, over-simplification and errors in interpreting drug studies[2].
They read the tryptophan evidence differently, writing that depletion studies “suggest a role for 5-HT in people vulnerable to depression and in those remitted on SSRI treatment”[2]. They also pointed to a brain imaging study that found reduced serotonin release capacity in 17 antidepressant-free people with a major depressive episode[2].
Their proposed conclusion was that the evidence indicates “a role for 5-HT in those vulnerable to or suffering from depression” and that molecular imaging suggests the system is “perturbed”[2]. That is a narrower claim than a population-wide serotonin shortage, and far from the advertising language described above.
The live dispute, then, is less about whether depression is a simple serotonin deficit and more about whether serotonin contributes in some people and some forms of the illness. Other biological leads, including inflammation, are summarized in what is the cause of depression.
U.S. adults who attributed a depression vignette to a chemical imbalance, 2006
Up from 67% in 1996 in the General Social Survey. Belief in the explanation grew over that decade while the share unwilling to work closely with the person described stayed flat.
How Many People Believe Depression Is a Chemical Imbalance?
Belief in the explanation rose as it spread. In the General Social Survey, the share of U.S. adults who called a chemical imbalance a likely cause of the depression described in a vignette grew from 67% in 1996 to 80% in 2006[3].
Over the same decade, the share citing a genetic problem rose from 51% to 64%, while the share attributing it to the normal ups and downs of life fell from 78% to 67%[3].
The authors concluded that the neurobiological view “translates into support for services but not into a decrease in stigma”[3]. The share unwilling to work closely with the person in the depression vignette was 46% in 1996 and 47% in 2006[3].
A 2018 follow-up of the same survey series, covering 4,129 adults across three waves, found that across the disorders studied, the early rise in chemical imbalance attributions “was followed by a decrease later”[10]. Between 2006 and 2018, the desire for social distance from the person with depression fell, including an 18.1% decrease for working with them[10].
The published follow-up does not report a 2018 chemical imbalance percentage for depression in its text[10], so the 2006 figure remains the latest exact U.S. number from this series. The 2022 umbrella review cites surveys suggesting that 80% or more of the public believe depression is caused by a chemical imbalance[1].
U.S. Public Beliefs About a Depression Vignette, 1996 vs. 2006
| Response | 1996 | 2006 |
|---|---|---|
| Likely cause: chemical imbalance | 67% | 80% |
| Likely cause: genetic problem | 51% | 64% |
| Likely cause: normal ups and downs of life | 78% | 67% |
| Likely cause: bad character | 38% | 32% |
| Endorses prescription medicine | 71% | 79% |
| Unwilling to work closely with the person | 46% | 47% |
Share of U.S. adults responding to a vignette describing major depression, General Social Survey modules[3].
1The bad character and work-closely changes were not statistically significant; the other four changes were.
Sources
- •Pescosolido et al., American Journal of Psychiatry, 2010
If Depression Isn’t a Chemical Imbalance, Why Do Antidepressants Work?
Whether a drug relieves symptoms and what caused the illness are separate questions. A 2018 network meta-analysis in The Lancet pooled 522 trials with 116,477 adults and found that all 21 antidepressants studied were more effective than placebo[4].
The effects were modest and the evidence uneven. Odds ratios for response ranged from 1.37 for reboxetine to 2.13 for amitriptyline, and the certainty of evidence was rated moderate to very low[4].
NIMH describes antidepressants as working “by changing how the brain produces or uses certain chemicals involved in mood or stress,” and notes they usually take 4 to 8 weeks to work[6].
Some newer drugs do not target serotonin. Esketamine (Spravato), approved for treatment-resistant depression, blocks the NMDA receptor, a glutamate receptor, and its label states that “the mechanism by which esketamine exerts its antidepressant effect is unknown”[11].
NIMH advises talking to a health care provider before starting or stopping any medication[6]. Trial results, side effects and discontinuation data by drug are in anti-depression meds.
Does the Chemical Imbalance Explanation Help or Hurt?
Clinicians, advocates and policy makers presented mental illnesses as medical diseases partly to counter low service use and stigma[3]. The evidence that the chemical imbalance message reduces blame is weak. In a 2014 experiment, people with a past or current depressive episode received a sham but credible biological test showing their symptoms were, or were not, caused by a chemical imbalance[5].
Those told they had a chemical imbalance did not blame themselves less. They were more pessimistic about their prognosis, expected less ability to regulate their mood, and rated medication as more credible and effective than psychotherapy[5].
The authors described these as “unhelpful and potentially iatrogenic effects” of attributing depressive symptoms to a chemical imbalance[5]. The U.S. survey data point the same way: neurobiological beliefs were linked to support for treatment but were generally unrelated to stigma, and where linked, they increased rejection rather than reducing it[3].
Stigma toward depression did fall between 2006 and 2018, a period in which chemical imbalance attributions overall declined[10]. That timing is a correlation in survey data, not evidence that one caused the other.
What Scientists Think Causes Depression Instead
No single cause has replaced serotonin. NIMH’s current summary is that genetic, biological, environmental and psychological factors all play a role[6]. One long-standing model treats depression as inherited or early vulnerability interacting with later stress; the evidence for it is reviewed in diathesis-stress theory.
Medical conditions and medications matter too. NIMH lists diabetes, cancer, heart disease and chronic pain as conditions that can co-occur with depression and worsen it, and notes that some medications cause side effects that contribute to depressive symptoms[6].
Brain chemistry remains part of the picture, including glutamate, the system targeted by esketamine[11], but as one mechanism among several rather than a single deficit with a single fix. Whether serotonin matters for particular subgroups of patients is still argued in the literature[2].
Frequently Asked Questions
Sources & References
- Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Molecular Psychiatry. Published 2022. Accessed October 2026. https://www.nature.com/articles/s41380-022-01661-0 [Link]
- Jauhar S, Arnone D, Baldwin DS, et al. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression. Molecular Psychiatry. Published 2023. Accessed October 2026. https://www.nature.com/articles/s41380-023-02095-y [Link]
- Pescosolido BA, Martin JK, Long JS, Medina TR, Phelan JC, Link BG. “A disease like any other”? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence. American Journal of Psychiatry. Published 2010. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC4429867/ [Link]
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. Published 2018. Accessed October 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32802-7/fulltext [Link]
- Kemp JJ, Lickel JJ, Deacon BJ. Effects of a chemical imbalance causal explanation on individuals' perceptions of their depressive symptoms. Behaviour Research and Therapy. Published 2014. Accessed October 2026. https://pubmed.ncbi.nlm.nih.gov/24657311/ [Link]
- National Institute of Mental Health. Depression. NIH Publication No. 24-MH-8079. National Institutes of Health. Published 2024. Accessed October 2026. https://www.nimh.nih.gov/health/publications/depression [Link]
- Lacasse JR, Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLOS Medicine. Published 2005. Accessed October 2026. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0020392 [Link]
- Pfizer. Zoloft (sertraline hydrochloride) prescribing information. U.S. Food and Drug Administration. Published 2009. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019839s070,020990s032lbl.pdf [Link]
- Ang B, Horowitz M, Moncrieff J. Is the chemical imbalance an ‘urban legend’? An exploration of the status of the serotonin theory of depression in the scientific literature. SSM - Mental Health. Published 2022. Accessed October 2026. https://www.sciencedirect.com/science/article/pii/S266656032200038X [Link]
- Pescosolido BA, Halpern-Manners A, Luo L, Perry B. Trends in public stigma of mental illness in the US, 1996-2018. JAMA Network Open. Published 2021. Accessed October 2026. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787280 [Link]
- Janssen Pharmaceuticals. Spravato (esketamine) nasal spray prescribing information. U.S. Food and Drug Administration. Published 2025. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf [Link]